{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jun M"],"funding":["school of medicine, stanford university"],"pagination":["e0276651"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9894485"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(2)"],"pubmed_abstract":["<h4>Objectives</h4>A phase II = design is used to evaluate the efficacy and feasibility of full dose docetaxel, platinum, and 5-fluorouracil (TPF) in a sequential chemoradiation treatment locally advanced (LA) or oligometastatic (OM) NPC patients.<h4>Materials and methods</h4>Twenty patients with LANPC (M0 cohort) and six patients with OMNPC (M1 cohort) received induction standard dose T (75 mg/m2) P (75 mg/m2) F (750 mg/m2 IVCI x 5days) x 3 followed by weekly cisplatin (40 mg/m2) or carboplatin (AUC 1.5) x 6 concurrent with radiation therapy of 70 Gy over 6.5-7 weeks. The first five patients received bevacizumab as part of an exploratory objective of hypoxia modification using correlative fluoromisonidasole (18F-MISO) PET CT scanning.<h4>Results</h4>The 18F-MISO imaging failed to reveal a"],"journal":["PloS one"],"pubmed_title":["In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation."],"pmcid":["PMC9894485"],"funding_grant_id":["[1105753 310 GHAQY]."],"pubmed_authors":["Colevas AD","McMillan A","Winters E","Lira R","Hara W","Le QT","Jun M","Quon A","Pinto H","Coty J","Lu R"],"additional_accession":[]},"is_claimable":false,"name":"In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation.","description":"<h4>Objectives</h4>A phase II = design is used to evaluate the efficacy and feasibility of full dose docetaxel, platinum, and 5-fluorouracil (TPF) in a sequential chemoradiation treatment locally advanced (LA) or oligometastatic (OM) NPC patients.<h4>Materials and methods</h4>Twenty patients with LANPC (M0 cohort) and six patients with OMNPC (M1 cohort) received induction standard dose T (75 mg/m2) P (75 mg/m2) F (750 mg/m2 IVCI x 5days) x 3 followed by weekly cisplatin (40 mg/m2) or carboplatin (AUC 1.5) x 6 concurrent with radiation therapy of 70 Gy over 6.5-7 weeks. The first five patients received bevacizumab as part of an exploratory objective of hypoxia modification using correlative fluoromisonidasole (18F-MISO) PET CT scanning.<h4>Results</h4>The 18F-MISO imaging failed to reveal a","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2026-05-28T19:00:49.438Z","creation":"2025-02-19T00:13:36.797Z"},"accession":"S-EPMC9894485","cross_references":{"pubmed":["36730145"],"doi":["10.1371/journal.pone.0276651"]}}